Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC

Pembrolizumab has become standard of care in early-stage triple-negative breast cancer (TNBC), but its expanding use may induce rare adverse events involving vascular and lymphatic endothelium. Capillary leak syndrome (CLS) remains an exceptionally rare toxicity of PD-1 blockade, scarcely reported i...

Descripció completa

Dades bibliogràfiques

Autors principals:	Naïla Benkalfate, Ghazi Hadjamara, Caroline Petorin, Magaly Zappa, Aimable Habonimana, Dufens Pierre Louis, Anne-Laure Chene, Jean-Patrick Clarke, Renan Liberge, Kinane Drak Alsibai, Claire Defrance, Barbara Pistilli, Baptiste Boulet, Soraya Benguerfi, Houari Aissaoui
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-05-01
Col·lecció:	Frontiers in Oncology
Matèries:	capillary leak syndrome (CLS) chylothorax immune-related adverse event (irAE) pembrolizumab triple-negative breast cancer (TNBC)
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1786343/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!